Clofazimine in the Treatment of Pulmonary Mycobacterium Avium Complex (MAC)

Phase 2Active Not RecruitingNCT02968212

Oregon Health and Science University102 enrolled

Overview

The purpose of this study is to evaluate the clinical effectiveness and safety of clofazimine when used to treat Mycobacteria avium complex (MAC) lung disease. Funding Source - FDA OOPD

Clofazimine is an orphan antibiotic drug that is no longer available through pharmacies in the United States. It is approved for the treatment of Mycobacterium leprae (leprosy) infections. Clofazimine has been used for many years off-label against other Mycobacterium, including Mycobacteria avium complex (MAC) lung disease, an increasingly prevalent infection in older Americans. The U.S. Food and Drug Administration currently oversees clofazimine use to treat MAC lung disease through a special investigational drug access program. However, to date, there is little understanding of the benefits and risks of clofazimine when used to treat MAC lung disease. Accordingly, the investigators have developed a randomized, placebo-controlled clinical trial to assess the clinical efficacy and safety of clofazimine. To be eligible, participants must have MAC lung disease, positive sputum cultures for MAC, and not currently taking antibiotics for MAC. Eligible participants (102 total enrolled) will be randomly given either clofazimine or placebo for 6 months, and followed closely by their treating physician. The percentage of participants who become culture negative in each group will be compared, as it is suspected that participants treated with clofazimine will be more likely to become culture negative. The safety of clofazimine will be measured as well as other potential benefits of the therapy including changes in lung function and quality of life.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

TRIPLE

Enrollment

102

Conditions

Mycobacterium Avium Complex

Interventions

ClofazimineDRUG

All participants in the experimental/treatment arm on this protocol will take a loading dose of 200 mg daily in soft capsule form of clofazimine for 16 weeks, dropping to 100 mg daily for the next 8 weeks.

sugar pillOTHER

All participants in the placebo arm on this protocol will take placebo in soft capsule form daily dropping to a smaller dose after 16 weeks to mirror the treatment arm dosing.

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * At least 2 positive MAC sputum cultures in the last 12 months with at least one obtained within 12 weeks prior to randomization * Meet ATS/IDSA 2007 pulmonary disease criteria * Adult males and females age 18 or over * Ability to provide informed consent for the use of study drug Exclusion Criteria: * Any patient who is unwilling or unable to provide consent or to comply with this protocol * Cavitary NTM disease * Patients who are currently taking or within the prior 12 weeks received any of the following: bedaquiline, or any component of ATS/IDSA multi-drug recommended therapy (macrolide, ethambutol, rifampin) for MAC * Current usage of inhaled amikacin, tobramycin, or gentamicin * In the judgment of the investigator, the patient is not a candidate for observation (e.g. severe symptoms, extensive disease burden) but rather should be treated with standard multi-drug therapy * Prior use of clofazimine that has resulted in an allergy to clofazimine or a severe adverse reaction * Current usage of medications associated with QT prolongation (see Appendix C for full list of prohibited concomitant medications) * Corrected QT (QTc) interval on electrocardiogram (ECG) \> 470 ms for females or 450 ms for males, calculated using Fridericia's formula60,61 * Advanced lung disease (FEV\<30%) * HIV * Active pulmonary tuberculosis requiring treatment at screening * Active pulmonary malignancy or chemotherapy or radiation within 1 year of screening * Use of chronic systemic corticosteroids at doses of 15 mg/day for more than 12 weeks * Prior lung or other solid organ transplant * Pregnancy, or breastfeeding that will continue during treatment

Locations (7)

National Jewish Health

Denver, Colorado, United States

University of South Florida

Tampa, Florida, United States

University of Chicago

Chicago, Illinois, United States

Louisiana State University

Baton Rouge, Louisiana, United States

Outcomes

Primary Outcomes

Change from Baseline sputum culture at 24 weeks

sputum will be processed for acid fast bacilli stain/acid fast bacterial culture. A semi-quantitative assessment will be made by colony count for patients.

Time frame: Sputum examined for culture change from Baseline at 24 weeks

Secondary Outcomes

Change from Baseline 6 Minute Walk Test at 24 weeks

Walking distance achieved in 6 minutes is assessed

Time frame: 6 Minute Walk Test results examined for change from Baseline at 24 weeks

Change from Baseline PROMIS Fatigue 7a short form questionnaire at 24 weeks

Self-administered questionnaire assessing a range of self-reported symptoms over the past seven days, from mild subjective feelings of tiredness to an overwhelming, debilitating, and sustained sense of exhaustion that likely decreases one's ability to execute daily activities and function normally in family or social roles. Fatigue is divided into the experience of fatigue (frequency, duration, and intensity) and the impact of fatigue on physical, mental, and social activities.

Time frame: PROMIS Fatigue 7a short form results examined for change from Baseline at 24 weeks

Change from Baseline Quality of Life-Bronchiectasis (QOL-B) with NTM module at 24 weeks

Self-administered questionnaire measuring 8 separate domains: Physical Functioning, Role Functioning, Vitality, Emotional Functioning, Social Functioning, Treatment Burden, Health Perceptions, and Respiratory Symptoms.

Time frame: QOL-B results examined for change from Baseline at 24 weeks

Change from Baseline CT scan at 24 weeks

CT scans will be computationally evaluated using custom software to provide volumetric assessment of NTM-associated abnormalities.

Time frame: CT scan examined for change from Baseline at 24 weeks

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.